{
    "paper_id": "637fe5080f52546f83866d64871599f5b1bfc85b",
    "metadata": {
        "title": "Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City",
        "authors": [
            {
                "first": "Kevin",
                "middle": [],
                "last": "Kalinsky",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Melissa",
                "middle": [
                    "K"
                ],
                "last": "Accordino",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Kristina",
                "middle": [],
                "last": "Hosi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Jessica",
                "middle": [
                    "E"
                ],
                "last": "Hawley",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [],
                "last": "Meghna",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Trivedi",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Katherine",
                "middle": [
                    "D"
                ],
                "last": "Crew",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Dawn",
                "middle": [
                    "L"
                ],
                "last": "Hershman",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Columbia University Irving Medical Center",
                    "location": {
                        "settlement": "New York",
                        "region": "NY",
                        "country": "USA"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "We collected demographic, treatment, and outcome data from established patients with stage I-IV BC at Columbia University Irving Medical Center (CUIMC) and COVID-19 + from 3/10/20 to 4/29/20 (data cut off). COVID-19 + was determined by reverse transcription-polymerase chain reaction (RT-PCR) by nasal swab and/or high clinical or radiographic suspicion. Initially, all outpatients with symptoms were referred to the emergency department (ED) for testing; however, outpatient testing, including at an ambulatory referral-based CUIMC fever clinic, was rapidly expanded with cobas\u00ae SARS-CoV-2 testing (Roche). This study was CUIMC Institutional Review Board approved.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods"
        },
        {
            "text": "Of the 4515 COVID-19 + total patients at CUIMC, 27 (0.6%) were established patients with a history of BC (Table 1) . Twenty-six (96%) were female; 15 (56%) White, 6 (22%) Black, and 12 (44%) identified as Hispanic. The median age was 56 years (range: 32-87), median body mass index was 28.5 kg/m 2 (range: 21-47), and 7 (26%) were current/former smokers. Co-morbidities included 15 (56%) with hypertension, 6 (22%) diabetes, and 6 (22%) pulmonary disease. The majority had stage I-III BC and 5 (19%) metastatic disease. In the 6 months prior to COVID-19 + , 16 (59%) received chemotherapy, 12 (44%) hormone therapy, 6 (22%) HER2-directed therapy, 1 (4%) checkpoint inhibitor, 6 (22%) breast surgery, and 2 (7%) radiation therapy. Prior to COVID-19 + , the last received therapy was chemotherapy for 14 patients [52%, median: 12 days (range 7-749)], 10 (37%) hormone therapy [median: 1 day (range 1-81)], and 3 (11%) HER2-directed antibodies without chemotherapy [median: 21 days (range 20-34)]. Treatment disruptions occurred in 20 patients (74%) due to COVID-19 +.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 105,
                    "end": 114,
                    "text": "(Table 1)",
                    "ref_id": null
                }
            ],
            "section": "Results"
        },
        {
            "text": "Most common symptoms were cough (70%), fever (52%), shortness of breath (52%), fatigue (30%), diarrhea (22%), and myalgia (19%), with 30% having \u2265 4 symptoms (Fig. 1) . Twenty-two patients (81%) had COVID-19 + confirmation by RT-PCR, 4 (15%) presumed COVID-19 + per clinical symptoms, and 1 (4%) based on imaging and symptoms. Eight (30%) were initially tested in the ED, of whom 3 were not admitted. The majority were tested in the outpatient setting: ambulatory oncology clinic (6 patients; 22%) or CUIMC fever clinic (8 patients: 30%).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 158,
                    "end": 166,
                    "text": "(Fig. 1)",
                    "ref_id": "FIGREF0"
                }
            ],
            "section": "Results"
        },
        {
            "text": "Of the 7 patients requiring hospitalization (26%), 3 were non-Hispanic Black, 3 Hispanic White, and 1 non-Hispanic White. Two received recent chemotherapy without targeted agents for early stage BC and 5 single-agent hormone therapy (1 for metastatic disease). Five admitted patient had at least 1 co-morbid disease, and 3 were former smokers. Five admitted patients required supplemental oxygen, and none needed intensive care-level support, including intubation or dialysis. All were discharged from the hospital. With a median follow-up from COVID-19 + diagnosis of 26 days (range 1-38), all patients were alive, except for an 87-yearold male with coronary artery disease, hypertension, and former smoker who received taxane-based chemotherapy for stage II BC seven days before symptoms.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Results"
        },
        {
            "text": "In our racially/ethnically diverse population of 27 COVID-19 + patients with BC, the majority (74%) did not require hospitalization, and one male with multiple co-morbidities died. This is of interest, as COVID-19 + males have reported worse outcomes than females [3] . While treatment disruptions occurred in most patients (74%), it is unknown whether this represents a deviation from other patients who develop infections on therapy. While larger series are needed to understand the impact of COVID-19 in patients with BC, these initial data are reassuring that a substantial number recover from their infection.",
            "cite_spans": [
                {
                    "start": 264,
                    "end": 267,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "Funding No funding to report. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion"
        },
        {
            "text": "Informed consent Informed consent was obtained from all individual participants included in the study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Compliance with ethical standards"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Oncol",
            "volume": "21",
            "issn": "20",
            "pages": "30096--30102",
            "other_ids": {
                "DOI": [
                    "10.1016/S1470-2045(20)30096-6"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "SARS-CoV-2 Transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Ouyang",
                    "suffix": ""
                },
                {
                    "first": "Mlk",
                    "middle": [],
                    "last": "Chua",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Xie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA Oncol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jamaoncol.2020.0980"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Grasselli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Italy. JAMA",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jama.2020.5394"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Percentage of COVID-19-related symptoms with which patients presented who had a history of stage I-IV breast cancer (n = 27). b Percentage of these patients who presented with 0, 1, 2, 3, or at least 4 COVID-19-related symptoms",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Baseline demographics, treatments, and outcomes in COVID-19 + patients with a history of breast cancer (n = 27)",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Conflict of interestNo conflicts are related to this particular study. For unrelated conflictions, Kevin Kalinsky served as a consultant/advisory board member for Immunomedics, Biotheranostics, Pfizer, Novartis, Eisai, Eli-Lilly, Amgen, and AstraZeneca. He has received institutional grants from Immunomedics, Novartis, Incyte, Genentech/Roche, Eli-Lilly, Pfizer, Calithera Biosciences, Acetylon, Seattle Genetics, Amgen, Zentalis Pharmaceuticals, and CytomX Therapeutics. Served on speakers' bureau for Eli-Lilly. Received travel expenses from Lilly and Astra Zeneca. Spouse was previously employed by Novartis, Array Biopharma, and Pfizer.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}